Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar;114(3):566-572.
doi: 10.1111/ejh.14363. Epub 2024 Dec 17.

Direct Oral Anticoagulants in Budd-Chiari Syndrome

Shrinjaya B Thapa  1   2 , Gabriel Roman Souza  1   2 , Mahati Paravathaneni  1   2 , Sean Cohen  1   2 , Turab Mohammed  1   2 , Damian A Laber  2   3   4
Affiliations
Review

Direct Oral Anticoagulants in Budd-Chiari Syndrome

Shrinjaya B Thapa et al. Eur J Haematol. 2025 Mar.

Abstract

Aims: Budd-Chiari syndrome (BCS) is managed by interventions aimed at relieving hepatic venous obstruction and anticoagulation. Despite robust data supporting the tolerability and efficacy of direct oral anticoagulants (DOACs) in patients with other venous thromboembolism, its utility in BCS is not well documented. This study aims to evaluate the efficacy and tolerability of DOACs in Primary BCS from the available literature.

Methods: Published studies that reported data on patients with BCS treated with DOACs were included.

Results: Two retrospective studies and nine case reports met the criteria for inclusion. The combined data from these two retrospective studies include 58 patients administered DOAC and 101 patients treated with VKA/LMWH. The combined re-stenosis or failure rates after percutaneous endovascular intervention, angioplasty, TIPS, or OLT were 17.2% for the DOAC group and 15.8% for the LMWH/VKA group. The incidence of major bleeding was 8.62% in the DOAC group and 5.94% in the LMWH/VKA group, while minor bleeding rates were 20.7% and 4.95%, respectively. Procedure-related bleeding was 4.5% in DOAC group and 12.8% in VKA/LMWH group. Nine case reports using apixaban in 3, rivaroxaban in 5, and one with dabigatran- described patients tolerating the treatment well and experiencing no major adverse events.

Conclusions: DOACs appear to be at least equally effective to LMWH/VKA for the anticoagulation of patients with BCS. We believe DOACs to be preferred over LMWH/VKA for the anticoagulation of patients with BCS due to the known advantages in administration, but randomized trials might be needed to answer this question.

Keywords: Budd‐Chiari syndrome; apixaban; dabigatran; direct oral anticoagulants; edoxaban; novel oral anticoagulants; rivaroxaban.

PubMed Disclaimer

References

    1. K. V. Menon, V. Shah, and P. S. Kamath, “The Budd‐Chiari Syndrome,” New England Journal of Medicine 350, no. 6 (2004): 578–585, https://doi.org/10.1056/NEJMra020282.
    1. H. Ferral, G. Behrens, and J. Lopera, “Budd‐Chiari Syndrome,” American Journal of Roentgenology 199, no. 4 (2012): 737–745, https://doi.org/10.2214/AJR.12.9098.
    1. P. Gavriilidis, G. Marangoni, J. Ahmad, and D. Azoulay, “State of the Art, Current Perspectives, and Controversies of Budd‐Chiari Syndrome: A Review,” Journal of Clinical Medicine Research 14, no. 4 (2022): 147–157, https://doi.org/10.14740/jocmr4724.
    1. S. Darwish Murad, A. Plessier, M. Hernandez‐Guerra, et al., “EN‐Vie (European Network for Vascular Disorders of the Liver). Etiology, Management, and Outcome of the Budd‐Chiari Syndrome,” Annals of Internal Medicine 151, no. 3 (2009): 167–175, https://doi.org/10.7326/0003‐4819‐151‐3‐200908040‐00004.
    1. P. G. Northup, J. C. Garcia‐Pagan, G. Garcia‐Tsao, et al., “Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases,” Hepatology 73, no. 1 (2021): 366–413, https://doi.org/10.1002/hep.31646.

LinkOut - more resources